VNS for Rheumatoid Arthritis & Inflammatory Disease

Core topics

Lessons in this module

Learning objectives

By the end of this module you will be able to

Lesson summary ↓Case study ↓Graded claims ↓Self-check ↓Vignettes ↓Glossary ↓

L01
State the SetPoint FDA indication (2025) and the biologic/tsDMARD-failure population.
L02
Explain the inflammatory reflex as the mechanistic basis for SetPoint.
L03
Interpret RESET-RA design and primary endpoints (ACR20/50/70, DAS28-CRP).
L04
Position SetPoint vs biologics for patients with infection risk, pregnancy planning, or biologic intolerance.
L05
Discuss future bioelectronic indications under investigation (Crohn's, IBD, lupus).

Expected takeaways

What you should walk away believing

→SetPoint is the first FDA-approved bioelectronic device for an autoimmune disease.
→Indication is narrow: mod-severe RA after biologic/tsDMARD failure.
→Mechanism translation (inflammatory reflex) opens doors well beyond RA.
→Long-term comparative data vs biologics is still accumulating.

Lesson · Core emphasis

What this means for you

Patient summary

A new implanted device called SetPoint can help some adults with rheumatoid arthritis when standard biologic medicines haven't worked. It's a brand-new approach — using electricity to dial down immune signaling instead of using a drug. It's not for everyone with RA, and your rheumatologist would need to refer you.

Clinician summary

SetPoint received FDA approval in 2025 for adults with mod-severe RA after inadequate response/loss of response/intolerance to ≥1 biologic or tsDMARD. Position as alternative when biologics fail or are contraindicated (infection risk, pregnancy planning, cost). Refer to centers with implant experience.

Advanced note

RESET-RA pivotal trial: 12-week sham-controlled phase + open-label. Discuss endpoint design (ACR20/50/70, DAS28-CRP), immunology readouts (TNF, IL-6 trajectories), and the broader implication that vagal stimulation can produce drug-comparable effects in autoimmune disease — opening doors for IBD, Crohn's, lupus exploration.

Evidence framework

Where this module sits on the device evidence map

SetPoint (2025) is the newest Tier 1 — and the first clean translation of the inflammatory reflex.

Tier map →Tier 1 →

Case study

RA patient with biologic failure

A 54-year-old with seropositive RA has failed adalimumab (loss of response) and tocilizumab (intolerance). She wants to avoid another biologic.

Question

Discuss SetPoint VNS as an option: criteria, expected response, AEs, and what you would monitor.

Evidence-graded claims

What the data says

A

SetPoint VNS is FDA-approved for RA after biologic failure

FDA PMA P240039 (2025).

F

VNS replaces all DMARDs

Adjunctive/alternative for specific failure population.

B

SetPoint produces ACR20/50 responses comparable to some biologic comparators

RESET-RA data; head-to-head vs biologics not yet definitive.

F

VNS is FDA-approved for Crohn's disease

Investigational only as of 2025.

C

SetPoint has favorable infection-risk profile vs biologics

Mechanistically plausible; long-term comparative data accumulating.

Objective self-check

Test the learning objectives

Score0 / 3(0 answered)

Objective · SetPoint indication.

Q1L01 — SetPoint FDA indication is for:

Objective · Inflammatory reflex as basis.

Q2L02 — Mechanistic premise of SetPoint?

Objective · Interpret RESET-RA endpoints.

Q3L03 — Pivotal trial supporting SetPoint approval?

Case vignettes

Apply it: real-world counseling scenarios

Short patient encounters that test your judgment, not your recall. Pick the most defensible response, then reveal the rationale and a sample coaching script you could actually say at the bedside.

Vignette proficiency

In progress · 0/3 submitted

Correct0/3 (0%)Pitfalls avoided0/5 (0%)Composite0

Composite weighting

Accuracy 60%Pitfalls 40%

← all pitfallsbalancedall accuracy →

Composite = 60% answer accuracy + 40% pitfalls avoided. Your weighting is saved for this module.

Order · randomized[1 · 2 · 3]

Vignette 1 of 3· source #1

Biologic-failure RA candidate

Objective · State the SetPoint FDA indication and biologic-failure population.

A 54-year-old with seropositive RA has failed adalimumab (loss of response) and tocilizumab (intolerance). She wants to avoid another biologic.

Most defensible counseling?

Vignette 2 of 3· source #2

Pregnancy-planning RA patient

Objective · Position SetPoint vs biologics for pregnancy-planning patients.

A 32-year-old with biologic-failure RA who is planning pregnancy asks whether SetPoint is a better fit than another biologic.

Most calibrated framing?

Vignette 3 of 3· source #3

Patient asks about Crohn's

Objective · Discuss future bioelectronic indications under investigation.

A patient with Crohn's disease asks whether SetPoint is approved for IBD.

Most accurate response?

Quick check

Test yourself

Q1The SetPoint System is relevant to:

Q2Best candidate for SetPoint?

Q3Mechanistic premise of SetPoint?

Flashcards

Lock it in

1 / 5

Front

SetPoint indication?

Click to flip

Glossary

Key terms & abbreviations

SetPoint: FDA-approved (2025) implanted VNS system for biologic-failure RA.
RESET-RA: Pivotal sham-controlled trial of SetPoint for RA.
ACR20/50/70: American College of Rheumatology composite response criteria (% improvement).
DAS28-CRP: Disease Activity Score in 28 joints using CRP — common RA outcome metric.
Biologic / tsDMARD: Targeted RA therapies (e.g. anti-TNF, JAK inhibitors). SetPoint is indicated after their failure or intolerance.
Cholinergic anti-inflammatory pathwayCAP: Vagal efferent → splenic nerve → α7-nAChR macrophages → ↓ TNF/IL-6.
Bioelectronic medicine: Treating disease by modulating neural circuits with electricity instead of drugs; SetPoint is the flagship in autoimmune disease.